证券代码：836149 证券简称：旭杰科技 公告编号：2025-043 旭杰科技（苏州）股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 4 月 17 日 15:00-17:00 活动地点：公 司 通 过 上 海 证 券 报 · 中 国 证 券 网 路 演 中 心 （https://roadshow.cnstock.com/）采用网络远程的方式召开 2024 年年度报 告业绩说明会。 上市公司接待人员：董事长丁杰先生、总经理金炜先生、董事会秘书、财务 总监陈吉容女士。 □现场参观 参会单位及人员：通过网络方式参加公司本次业绩说明会的投资者。 2、问：请介绍一下公司收购中新旭德 47%股份，对公司的影响，谢谢！ 答：尊敬的投资者您好！2025 年 2 月，公司完成了收购中新旭德 47%股权 事项，中新旭德成为 ...

证券代码：000833 证券简称：粤桂股份 编号：2025-001 广西粤桂广业控股股份有限公司 投资者活动记录表 | | □特定对象调研 | □分析师会议 | | --- | --- | --- | | 投资者关系活 | □媒体采访 | √业绩说明会 | | 动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □电话会议 | | | □其他： （请文字说明其他活动内容） | | | 参与单位名称 | | | | | | 粤桂股份2024年度业绩说明会采用网络远程方式进行，面向全体投资者 | | 及人员姓名 | | | | 时间 | 2025 年 4 月 18 日 15:00-16:30 | | | 地点 | | 1.深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目； | | | 2.价值在线（https://eseb.cn/1nmf8GLivkc）网络互动 主持人：粤桂股份 | | | | 董事长：刘富华 | | | | 董事、总经理：卢勇滨 | | | 公司接待人员 | 独立董事：胡咸华 | | | 姓名 | 独立董事：刘祎 | | | | 独立 ...

| 度。未来，公司将通过产品竞争力提升和市场风险分散的双 | | --- | | 重举措，推动出口业务可持续发展。谢谢！ | | 2、分析师认为钢铁行业处于周期底部，公司如何看待 | | 2025 年需求？是否会通过并购（如山东鹰轮）或减产应对 | | 市场波动？如何平衡产能利用率与利润？ | | 答：当前钢铁行业正处于周期性调整阶段，2025 年市 | | 场需求保持审慎乐观态度。随着国家"十四五"规划重大 | | 项目持续推进，以及新能源装备、汽车制造等下游行业的结 | | 构性增长，高品质特种钢领域仍将保持稳定需求。公司将以 | | 智能化改造提升生产能力，通过持续强化技术创新，提升新 | | 品开发能力，提高高端产品市场占比率。未来，公司将以 | | "高端化、智能化、绿色化"为方向，通过产品结构优化和 | | 技术升级来平衡产能与利润。谢谢！ | | 3、公司是否计划扩大高利润产品（如特种钢、汽车用 | | 钢）的产能？未来是否有新的技术突破？ | | 答：公司高度重视高利润产品的战略布局和技术创新。 | | 2024 年公司研发投入 5.82 亿元，占营收总额 4.04%。公司 | | 依托省级企 ...

Financial Performance - In 2024, the company achieved a revenue of CNY 41.906 billion, a year-on-year increase of 3.16% [4] - The net profit attributable to shareholders was CNY 3.512 billion, up 23.72% year-on-year [4] - The net profit after deducting non-recurring gains and losses was CNY 3.352 billion, reflecting a growth of 22.48% [4] - Compared to 2021, revenue and net profit grew by 21.24% and 52.59%, respectively [4] Business Segments Performance Pharmaceutical Industry - The pharmaceutical segment generated a revenue of CNY 13.811 billion, with a year-on-year growth of 13.05% [5] - The net profit for this segment was CNY 2.876 billion, increasing by 29.04% [5] - R&D investment in the pharmaceutical industry reached CNY 2.678 billion, a 16.77% increase [5] Aesthetic Medicine - The domestic aesthetic medicine subsidiary reported a revenue of CNY 1.139 billion, growing by 8.32% [6] - The UK subsidiary, Sinclair, generated approximately CNY 0.967 billion, a decline of 25.81% due to global economic challenges [6] Industrial Microbiology - The industrial microbiology segment achieved a revenue of CNY 0.711 billion, a significant increase of 43.12% [25] - Growth rates for specific areas included 38% for specialty raw materials and intermediates, 20% for xRNA, and 142% for health and biological materials [25] R&D and Product Development - The company has over 80 innovative drug candidates in its pipeline [5] - The oral small molecule GLP-1 receptor agonist HDM1002 has shown promising results in clinical trials, with over 800 participants [17] - The ADC pipeline includes more than 12 projects, with ongoing clinical trials for several candidates [14] Market Strategy and Future Outlook - The company plans to actively participate in medical insurance negotiations for new products [6] - There is a focus on expanding market presence in both domestic and international markets, particularly in the aesthetic medicine sector [26] - The company anticipates a gradual recovery in overseas aesthetic medicine markets [26] Investor Relations and Communication - The annual performance meeting was attended by 381 institutional and individual investors [2] - The chairman emphasized the commitment to high-quality development and strategic goals for the upcoming three-year plan [27]

Group 1: Company Overview and Achievements - Qinghai Salt Lake Industry Co., Ltd. is a key member of China Minmetals Corporation, leveraging the unique resource advantages of the Chaka Salt Lake for comprehensive resource development [1][2]. - The Chaka Salt Lake covers an area of 5,856 square kilometers, making it the largest soluble potassium and magnesium salt deposit in China and a significant player globally [1][2]. - The company has achieved a stable annual production capacity of 5 million tons of potassium fertilizer, ranking fourth globally, and 40,000 tons of lithium carbonate, leading the domestic brine lithium extraction sector [2][3]. Group 2: Financial Performance - In 2024, the company reported total revenue of 15.134 billion yuan and a net profit attributable to shareholders of 4.663 billion yuan [3][13]. - As of December 31, 2024, total assets reached 45.783 billion yuan, with liabilities of 6.189 billion yuan, resulting in a low debt-to-asset ratio of 13.52% [3][13]. - Shareholder equity increased by 14.63% year-on-year, amounting to 36.575 billion yuan, reflecting strong profitability and growth [3][13]. Group 3: Strategic Goals and Development Plans - The year 2025 marks a pivotal year for the company as it integrates into the China Minmetals system, aiming to accelerate the construction of a world-class salt lake industry base [4][14]. - The company plans to achieve a production capacity of 10 million tons of potassium fertilizer and 200,000 tons of lithium salt by 2030, with a vision to establish a comprehensive salt lake industry cluster by 2035 [4][20]. - The strategic development path includes focusing on one goal, adhering to three musts, and leveraging four roles to enhance competitiveness and sustainability [5][7][9]. Group 4: Operational Strategies - The company emphasizes high-quality development by leveraging China Minmetals' expertise in project investment and management to enhance production capabilities [7][8]. - It aims to implement lean management practices to optimize operations and improve efficiency, ensuring robust performance in competitive markets [7][8]. - The company is committed to addressing capability gaps by embracing digital and green technologies to enhance production quality and operational resilience [8][9]. Group 5: Risk Management and Social Responsibility - A comprehensive risk management system is in place to identify and mitigate various risks, ensuring stable operations [2][8]. - The company actively engages in social responsibility initiatives, enhancing its corporate image and contributing positively to the community [2][11]. - Safety culture is prioritized, with measures in place to ensure safe production practices and environmental protection [10][11]. Group 6: Investor Relations and Future Outlook - The company maintains close communication with investors, providing timely updates on strategic developments and performance [11][24]. - Plans for future capital management include a focus on sustainable growth and potential dividend policies as financial conditions improve [17][24]. - The company is exploring international opportunities to enhance resource acquisition and market presence, particularly in potassium fertilizer [20][24].

Group 1: Investor Relations Activity - The company held an annual performance briefing on April 17, 2025, via the "Investor Relations Interactive Platform" [3] - Key personnel present included the Chairman, General Manager, and other executives [3] Group 2: Performance Overview - The company faced a revenue decline in 2024 primarily due to underperformance in the defense market, which significantly impacted revenue and profit [6] - R&D investment was high, accounting for 11.33% of revenue, due to an increase in new projects [6] - The commercial aerospace sector did not meet expected launch plans, affecting revenue growth [6] - Despite significant revenue growth in the civil communication sector, its low gross margin limited profit contributions [6] Group 3: Financial Health - As of December 31, 2024, net accounts receivable amounted to 565.88 million yuan, a 28.89% increase from the beginning of the period [7] - Accounts receivable represented 39.66% of total assets and 55.94% of current assets, with 82.08% of accounts receivable aged within one year [7] - The company plans to implement strict sales management and credit control measures to mitigate operational risks [7] Group 4: Cost Control and Competitive Strategy - The company is implementing efficiency projects to achieve cost reduction, including material optimization and automation [9] - It aims to enhance R&D investment focusing on low-cost, miniaturized, high-frequency, and integrated technologies [10] - A specialized R&D team will be established to ensure forward-looking research in core technology areas [10] Group 5: Market Outlook - The commercial satellite sector is expected to maintain stable growth in 2025, with ongoing collaboration with core customers [11] - The company offers low-cost, high-reliability interconnection solutions for the aerospace sector, supporting multiple space missions [12] Group 6: Corporate Governance - The company has established a value management system in response to regulatory requirements and aims for sustainable growth [13] - It emphasizes high-quality information disclosure and investor engagement to enhance understanding of its strategic goals [13] Group 7: New Product Development - The 400G high-speed copper cable prototype line was completed by the end of 2024, with ongoing product expansion and customer validation [14] - The expected contribution of this product to the company's performance in 2025 is anticipated to be minimal [14]

证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 编号：2025-001 | | □ □ 分析师会议 | 特定对象调研 | | --- | --- | --- | | 投资者关系 活动类别 | □ 业绩说明会 | □ 媒体采访 | | | □ 路演活动 | □ 新闻发布会 | | | □ √ 其他（线上会议） | 现场参观 | | 参与人员 | 华泰证券、西南证券、东北证券、国盛证券、国金证券、东吴证券、中信建投 证券、中信证券、国信证券、中邮证券、西部证券、南方基金、大成基金、博 | | | | 证券、华福证券、申万宏源证券、兴业证券、国联民生证券、国信证券、中泰 | | | | 时基金、上海人寿、招商基金、新华基金、中航基金、友邦人寿、红杉中国、 | | | | 华夏基金、广发基金、中银基金、景顺长城基金、IDG 资本、工银瑞信等七十 | | | | | 余位投资者 | | 时间 | 日 2025 | 年 月 4 16 | | 地点 | | 线上沟通 | | 上市公司接 | 董事长、总经理：董凡 | | | | 董事 ...

证券代码：002428 证券简称：云南锗业 云南临沧鑫圆锗业股份有限公司 投资者关系活动记录表 编号：2025-004 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 ☑业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 （请文字说明其他活动内容） | | 活动参与人员 | 参与云南锗业 2024 年度网上业绩说明会的投资者。 | | 时间 | 2025 年 4 月 18 日 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | 上市公司接待人 | 董事长、总经理：包文东； | | 员姓名 | 董事、副总经理、财务总监：杨元杰； | | | 独立董事：方自维、龙超、黄松； | | | 副总经理、董事会秘书：金洪国。 | | | 公司于 2025 年 4 月 18 日（周五）15：00-17：00 在全景网举办 2024 | | | 年度网上业绩说明会，本次年度业绩说明会采用网络远程的方式举行，问答 环节主要内容如下： | | | 1、关于现金流与净利润增长不匹配的问题，年报显 ...

证券代码：300548 证券简称：博创科技 博创科技股份有限公司 博创科技 2024 年度业绩说明会 投资者活动记录表 编号：2025-001 4.请问贵公司未来盈利增长的主要驱动因素有哪些？ 答：感谢您对公司的关注！公司未来盈利增长的主要驱动因素在于稳定的 国际局势、积极的财政政策、AI 需求的持续增长以及公司在高速互联上的 技术突破和领先等多个方面。 5. 公司能否尽快提前预披露一季报，坚定小股东信心？ 答：您好！公司《2025 年第一季度报告》将于 4 月底披露，敬请关注。 6.贵司美国业务占比多少？关税大战对贵司的影响多大？贵司在英国和印 尼有设厂，海外产能是否足够降低关税带来的影响？ | | □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 | | --- | --- | | 投资者关系活动 | | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □电话会议 | | | □其他： （请文字说明其他活动内容） | | 参与单位名称 | 博创科技2024年度业绩说明会采用网络远程方式进行，面向全体投资者 | | 及人员姓名 | | | 时间 | 年 月 日 2025 4 18 15 ...